Cryoport Q1 2026 Results: Revenue Jumps 26% Supporting Record 766 Clinical Trials and 21 Commercial Cell Gene Therapies

Key Takeaways

• Cryoport’s commercial cell and gene therapy revenue increased 26% year-over-year to $9.1 million in Q1 2026
• The company now supports a record 766 global clinical trials, including 91 Phase 3 studies, representing a net increase of 55 trials
• Number of commercially approved cell and gene therapies supported by Cryoport reached 21 as of March 31, 2026

---

Cryoport Delivers Strong Q1 2026 Performance

Cryoport, a leading provider of temperature-controlled supply chain solutions for the life sciences industry, reported robust first quarter 2026 financial results, highlighting significant growth in its cell and gene therapy (CGT) business segment.

The company’s revenue from supporting commercial CGTs surged 26% year-over-year to $9.1 million, demonstrating the expanding market demand for specialized logistics services in the rapidly growing cell and gene therapy sector. This growth reflects the increasing number of approved therapies reaching commercial stages and the critical need for ultra-low temperature storage and transportation services.

Record Clinical Trial Support Expansion

As of March 31, 2026, Cryoport supported 766 global clinical trials, marking a net increase of 55 trials compared to the same period in 2025. Notably, 91 of these trials are in Phase 3, the final stage before regulatory approval, indicating a strong pipeline of potential new therapies that could transition to commercial support in the coming years.

This expansion in clinical trial support positions Cryoport to benefit from the continued growth in cell and gene therapy development, as pharmaceutical and biotechnology companies increasingly rely on specialized logistics providers to maintain the integrity of temperature-sensitive biological materials throughout the supply chain.

Market Implications and Future Outlook

The 26% revenue growth in commercial CGT support, combined with the record number of clinical trials, underscores the critical role Cryoport plays in the cell and gene therapy ecosystem. As more experimental therapies advance through clinical development and receive regulatory approval, the demand for Cryoport’s specialized services is expected to continue growing.

The company’s ability to support 21 commercially approved CGTs demonstrates its established market position and operational capabilities in handling complex logistics requirements for advanced therapies that often require storage at ultra-low temperatures and rapid, reliable delivery to treatment centers worldwide.

---

Frequently Asked Questions

What does Cryoport’s growth mean for cell and gene therapy patients?

The expansion indicates more cell and gene therapies are advancing through development and reaching patients, with improved logistics infrastructure supporting reliable delivery of these life-saving treatments.

How significant is the 26% revenue growth for Cryoport’s business?

The 26% year-over-year growth in commercial CGT revenue to $9.1 million demonstrates strong market demand and Cryoport’s successful positioning in the rapidly expanding cell and gene therapy logistics market.

What does supporting 766 clinical trials mean for future growth?

Supporting 766 trials, including 91 Phase 3 studies, creates a substantial pipeline of potential commercial clients as these experimental therapies advance toward regulatory approval and market launch.